LAG3 antibody (AA 23-245)

Catalog No. ABIN7092960

This Rabbit Monoclonal antibody specifically detects LAG3 in ELISA and FACS. It exhibits reactivity toward Human.

Quick Overview for LAG3 antibody (AA 23-245) (ABIN7092960)

Target: LAG3 (Lymphocyte-Activation Gene 3 (LAG3))

Reactivity: Human

Host: Rabbit

Clonality: Monoclonal

Conjugate: This LAG3 antibody is un-conjugated

Application: ELISA, Flow Cytometry (FACS)

Clone: DM160

Product Details anti-LAG3 Antibody

Binding Specificity: AA 23-245

Purification: Purified from cell culture supernatant by affinity chromatography

Immunogen: Recombinant human LAG3(Leu23-Leu245) (ABIN6964105) produced by using human HEK293 cells

Isotype: IgG

Application Details

Application Notes: ELISA 1/5000-10000,Flow Cyt 1/100

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Reconstitute with deionized water

Buffer: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose is added as protectants before lyophilization.,0.1 % Procline 300

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,-80 °C

Storage Comment: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

Expiry Date: 12 months

Target Details for LAG3

Target: LAG3 (Lymphocyte-Activation Gene 3 (LAG3))

Alternative Name: LAG3

Background: Synonyms:LAG-3, CD223
Description:Lymphocyte-activation protein 3 belongs to Ig superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. [provided by RefSeq, Jul 2008]

Molecular Weight: 57.4KDa

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints